Comparative Pharmacology
Head-to-head clinical analysis: NORGESTIMATE ETHINYL ESTRADIOL versus OGEN 5.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NORGESTIMATE ETHINYL ESTRADIOL versus OGEN 5.
NORGESTIMATE; ETHINYL ESTRADIOL vs OGEN 5
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive containing norgestimate (a progestin) and ethinyl estradiol (an estrogen). The primary mechanism is suppression of gonadotropins (FSH and LH) via negative feedback on the hypothalamic-pituitary-ovarian axis, preventing ovulation. Additional effects include thickening cervical mucus (inhibiting sperm penetration) and altering endometrial receptivity.
Estrogen replacement; binds to estrogen receptors, activating gene transcription for estrogenic effects in target tissues.
Oral, one tablet daily at the same time for 21 days, followed by 7 placebo tablets.
0.625 mg orally once daily, adjusted based on response.
None Documented
None Documented
Norgestimate: terminal half-life of norelgestromin (active metabolite) is 27.6 ± 7.8 hours; ethinyl estradiol: terminal half-life is 17.5 ± 6.3 hours. Steady state achieved within 14 days.
Terminal elimination half-life of estrone (primary active metabolite) is approximately 20 hours; steady-state concentrations achieved within 6-8 days. Half-life of estradiol is shorter (1-2 hours) but clinically the estrogenic effect correlates with estrone.
Norgestimate metabolites are primarily excreted via urine (60-80%) and feces (35-49%) as glucuronide and sulfate conjugates; ethinyl estradiol is excreted in urine (40%) and feces (60%) as conjugates.
Renal (primarily as conjugated metabolites); approximately 50-80% of an oral dose is excreted in urine, with about 20% in feces via biliary elimination.
Category D/X
Category C
Progestin + Estrogen
Estrogen